CompletedNCT00216918
Neuropsychological changes during atomoxetine treatment in children with ADHD
About this title
Read the official source — NCT00216918Medication studyAges 6–10Canada
Understand this study
Who was this study for?
Listed age limits: 6 years to 10 years.
- Listed locations
- QuébecSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 6 Years to 10 Years
- Official registry ID
- NCT00216918
- Official title
Show the full official title
An Open-Label Pilot Study of Atomoxetine Hydrochloride to Evaluate Neuropsychological Function in Children Ages 6 to 10 Years With Attention-Deficit/Hyperactivity Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Québec
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 10 years.
